Pharmaceutical giants Fuji Pharma and Alvotech have recently announced that they are collaborating for the development and commercialization of biosimilars in Japan. Under the agreement, Alvotech will be looking after the development and supply of biosimilar assets, while Fuji Pharma will be taking control of …
Cantel Medical Corporation, a U.S.-based medical equipment company, has reportedly announced that it intends to acquire Omnia S.p.A, a renowned Italian dental surgical consumables provider. With the acquisition, Cantel Medical Corp. aims to further foray into the European market – which Omnia is a leading …
Verily, the life sciences division of Google’s parent Alphabet, has recently announced that it has halted the development of a smart contact lens designed for helping to monitor sugar levels. It was one of the company’s oldest and most high-profile projects and had begun in …
Next-gen cyber solutions provider, BlackRidge Technology International has reportedly partnered with leading healthcare technology provider ImagineMed, to protect patient data and ImagineMed’s delivery model. As per trusted sources, the partnership will enable BlackRidge to develop a software-defined security perimeter that safeguards patient data when at …
U.S. biotechnology firm, United Therapeutics Corp. has recently invested $800 million cash upfront to grab rights to Arena Pharmaceuticals’ pulmonary arterial hypertension (PAH) drug, Ralinepag. As per sources, the firm’s executive crew believes that the acquired rights would enable the company to gain huge revenues …
British engineering conglomerate, Smiths Group plc has recently announced plans to spin off its medical devices division to focus on emerging as a dedicated industrial technology company. As per a statement, Smiths claims that the parting will allow the medical unit, which develops artificial hip …
The Ministry of Science and Technology has recently announced that India and the United Kingdom have both signed a Memorandum of Understanding (MoU) for collaborating on cancer research at the Inaugural Researchers’ Conference in New Delhi. The India-UK Cancer Research Initiative focused on developing affordable …
IMV Incorporation, a clinical stage biopharmaceutical company, has reportedly declared the expansion of its clinical program through a Phase 2 basket trial assessing its prime drug, DPX-Survivac, combined with KEYTRUDA (pembrolizumab) and cyclophosphamide, in patients suffering from recurrent or advanced solid tumors. Frederic Ors, Chief …
Silence Therapeutics PLC, a UK based biotechnology firm, has reportedly grabbed headlines by announcing the launch of its first-in-human clinical test, anticipated to kick off in the second half of 2019. For the record, Silence Therapeutics boasts of expertise in RNA interference, which is a …
